Time to question long-term safety of routine scheduled inhaled beta-2-agonist treatment for COPD

Editorial

Douglas C McCrory. J Gen Intern Med. 2006 Oct.

. 2006 Oct;21(10):1123-4.

doi: 10.1111/j.1525-1497.2006.00602.x.

No abstract available

Comment on

Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.
Salpeter SR, Buckley NS, Salpeter EE. Salpeter SR, et al. J Gen Intern Med. 2006 Oct;21(10):1011-9. doi: 10.1111/j.1525-1497.2006.00507.x. J Gen Intern Med. 2006. PMID: 16970553 Free PMC article.

1. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med. 2006;21:1011–1019. - PMC - PubMed
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Bethesda, MD: Global Initiative for Chronic Obstructive Lung Disease, World Health Organization, National Heart, Lung and Blood Institute; 2005. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. World Health Organization (WHO), National Heart, Lung and Blood Institute (NHLBI) - PubMed
1. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:842–6. - PubMed
1. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews. 2006. Issue 2. Art. No.: CD001387.pub2. doi 10.1002/14651858.CD001387.pub2. - DOI - PMC - PubMed
1. Combivent Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997;112:1514–21. - PubMed